JPRN-jRCT2080221553UnknownPhase 1
A Phase I Study of weekly ABI-007 in Combination with TS-1 in Patients with Metastatic Breast Cancer
Conditions
Trial Snapshot
- Phase
- Phase 1
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to <= 74age old (—)
- Sex
- Female
Inclusion Criteria
- •Patient has no prior chemotherapy or one for metastatic breast cancer. No prior chemotherapy of Taxanes or TS-1 for metastatic breast caner.
- •- Patient has no over-expressed HER2 for IHC or FISH.
Exclusion Criteria
- •- Patient has recurrent disease within 12 months following the end of neo-adjuvant or adjuvant chemotherapy with a Taxane-containing regimen.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Efficacy of ABI-007 plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients with Metastatic Pancreatic Cancer.metastatic pancreatic cancerMedDRA version: 14.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864EUCTR2013-001463-23-FRGERCOR114
Completed
Phase 1
Phase I clinical study of ABI-007 in combination with gemcitabinepancreatic cancerJPRN-jRCT2080223124Taiho Pharmaceutical Co., Ltd.40
Active, not recruiting
Not Applicable
A clinical trial to find out whether ABI-007 given together with gemcitabine is as safe and effective as gemcitabine alone, in the treatment of patients with pancreatic cancer that has spread to other organs (metastatic adenocarcinoma of the pancreas)Metastatic adenocarcinoma of the pancreasMedDRA version: 14.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-011305-17-ITABRAXIS BIOSCIENCE LLC AN INDIRECT SUBSIDIARY OF CELGENE CORPORATIO842
Active, not recruiting
Phase 1
A clinical trial to find out whether ABI-007 given together with gemcitabine is as safe and effective as gemcitabine alone, in the treatment of patients with pancreatic cancer that has spread to other organs (metastatic adenocarcinoma of the pancreas)Metastatic Adenocarcinoma of the PancreasMedDRA version: 14.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-011305-17-ESAbraxis BioScience, LLC, an indirect subsidiary of Celgene Corporation842
Active, not recruiting
Not Applicable
A clinical trial to find out whether ABI-007 given together with gemcitabine is as safe and effective as gemcitabine alone, in the treatment of patients with pancreatic cancer that has spread to other organs (metastatic adenocarcinoma of the pancreas)Metastatic Adenocarcinoma of the PancreasMedDRA version: 14.1Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 100000004864EUCTR2009-011305-17-DEAbraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation842